Linked Life Data

7641750

Source:http://linkedlifedata.com/resource/pubmed/id/7641750

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1995-9-19
pubmed:abstractText
Iodine-131 3F8, a murine IgG3 monoclonal antibody that targets to GD2-bearing tumors, was administered intravenously to 12 patients with brain tumors. Six patients received 2 mCi (0.74 Bq) of 131I-3F8, five patients 10 mCi (3.7 Bq)/1.73 m2 of 131I-3F8, and one patient 2.6 mCi (0.96 Bq) of 124I-3F8, with no side-effects. Nine of 11 malignant gliomas and the single metastatic melanoma showed antibody localization, with the best tumor delineation on single-photon emission tomography (SPET) following 10 mCi (3.7 Bq)/1.73 m2 dose. No nonspecific uptake in the normal craniospinal axis was detected. There was no difference in the pharmacokinetics of low-dose versus the higher-dose antibody groups; plasma and total-body half-lives were 18 h and 49 h, respectively. Surgical sampling and time-activity curves based on quantitative imaging showed peak uptake in high-grade glioma at 39 h, with a half-life of 62 h. Tumor uptake at time of surgery averaged 3.5 x 10(-3) %ID/g and peak activity by the conjugate view method averaged 9.2 x 10(-3) %ID/g (3.5-17.8). Mean radiation absorption dose was 3.9 rad per mCi injected (range 0.7-9.6) or 10.5 cGy/Bq (range 1.9-26). There was agreement on positive sites when immunoscintigraphy was compared with technetium-99m glucoheptonate/diethylene triamine penta-acetic acid planar imaging, thallium-201 SPET, and fluorine-18 fluorodeoxyglucose positron emission tomography. Taken together, these data suggest that quantitative estimates of antibody targeting to intracranial tumors can be made using the modified conjugate view method.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0340-6997
pubmed:author
pubmed:issnType
Print
pubmed:volume
22
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
419-26
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:7641750-Adolescent, pubmed-meshheading:7641750-Adult, pubmed-meshheading:7641750-Aged, pubmed-meshheading:7641750-Brain Neoplasms, pubmed-meshheading:7641750-Child, pubmed-meshheading:7641750-Deoxyglucose, pubmed-meshheading:7641750-Female, pubmed-meshheading:7641750-Fluorine Radioisotopes, pubmed-meshheading:7641750-Fluorodeoxyglucose F18, pubmed-meshheading:7641750-Glioblastoma, pubmed-meshheading:7641750-Humans, pubmed-meshheading:7641750-Iodine Radioisotopes, pubmed-meshheading:7641750-Male, pubmed-meshheading:7641750-Middle Aged, pubmed-meshheading:7641750-Organotechnetium Compounds, pubmed-meshheading:7641750-Radioimmunodetection, pubmed-meshheading:7641750-Sugar Acids, pubmed-meshheading:7641750-Technetium Tc 99m Pentetate, pubmed-meshheading:7641750-Thallium Radioisotopes, pubmed-meshheading:7641750-Tomography, Emission-Computed, pubmed-meshheading:7641750-Tomography, Emission-Computed, Single-Photon
pubmed:year
1995
pubmed:articleTitle
Quantitative studies of monoclonal antibody targeting to disialoganglioside GD2 in human brain tumors.
pubmed:affiliation
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, U.S. Gov't, Non-P.H.S.